ZIM Laboratories has seen a positive movement in its stock, trading at Rs. 112.00, an increase of 1.95 points or 1.77% from the previous close of Rs. 110.05 on the BSE.

The stock opened at Rs. 112.50, reaching a high of Rs. 113.10 and a low of Rs. 109.80 during the session, with 5196 shares traded so far.

This BSE group 'B' stock, with a face value of Rs. 10, has recorded a 52-week high of Rs. 151.75 on August 4, 2023, and a 52-week low of Rs. 89.90 on March 13, 2024.

Over the past week, the stock has fluctuated between a high of Rs. 115.30 and a low of Rs. 104.80. The company's current market capitalization stands at Rs. 535.98 crore.

The company's promoter holding is at 33.26%, with non-institutional investors holding the remaining 66.73%.

ZIM Laboratories' fully-owned European subsidiary, SIA ZIM Laboratories, has obtained Marketing Authorisation (MA) from INFARMED (Portugal) – the Portuguese National Authority of Medicines and Health Products – for its New Innovative Product (NIP) ‘Azithromycin for Oral Suspension 200 mg/5ml’ in Portugal.

This marks ZIM's first Marketing Authorisation for its New Innovative Products in Europe. The Azithromycin Oral Suspension is uniquely formulated to mask the bitter taste, making it easier for patients, especially children, who have difficulty swallowing.

According to IQVIA, the EU market for this product was approximately $300 million in 2022. Furthermore, ZIM is targeting additional markets in Southeast Asia, Oceania, Latin America, and MENA, which collectively have a market size of around $900 million.

ZIM Laboratories specializes in the manufacturing, formulation, and distribution of drug delivery systems, focusing on the development of generic pharmaceutical products.